脂肪因子Chemerin与肝纤维化发生发展的关系

张欣媛, 张诺琪, 于国慧, 任文帅, 王亚玲

PDF(904 KB)
中国高校科技期刊信息汇聚平台
PDF(904 KB)
临床肝胆病杂志 ›› 2025, Vol. 41 ›› Issue (1) : 164-169. DOI: 10.12449/JCH250125
综述

脂肪因子Chemerin与肝纤维化发生发展的关系

作者信息 +

Association of the adipokine Chemerin with the development and progression of liver fibrosis

Author information +
History +

摘要

肝纤维化是各种慢性肝病向肝硬化发展的共同病理过程，影响慢性肝病患者的预后。Chemerin是一种新型脂肪因子，参与机体糖脂代谢和炎症，并且其表达水平在多项研究中显示与肝纤维化程度具有相关性，提示Chemerin可能通过调节代谢和炎症参与肝纤维化进程。Chemerin在辅助诊断和干预肝纤维化进程方面表现出一定的潜力。本文对Chemerin在肝纤维化过程中可能发挥的作用及机制进行综述，以期为肝纤维化的诊疗提供新思路。

Abstract

Liver fibrosis is the common pathological process in the progression of various chronic liver diseases to liver cirrhosis， and it greatly affects the prognosis of patients with chronic liver diseases. As a novel adipokine， Chemerin participates in the metabolism of glucose and lipids and inflammation， and various studies have shown that the expression level of Chemerin is correlated with the degree of liver fibrosis， suggesting that Chemerin may be involved in the process of liver fibrosis by regulating metabolism and inflammation. Chemerin has shown certain potential in the auxiliary diagnosis of liver fibrosis and the intervention against the progression of liver fibrosis. This article reviews the potential role and mechanism of action of Chemerin in the process of liver fibrosis， in order to provide new ideas for the diagnosis and treatment of liver fibrosis.

关键词

肝纤维化 / 脂肪因子类 / Chemerin

Key words

Hepatic Fibrosis / Adipokines / Chemerin

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
张欣媛 , 张诺琪 , 于国慧 , 等. 脂肪因子Chemerin与肝纤维化发生发展的关系. 临床肝胆病杂志. 2025, 41(1): 164-169 https://doi.org/10.12449/JCH250125
Xinyuan ZHANG, Nuoqi ZHANG, Guohui YU, et al. Association of the adipokine Chemerin with the development and progression of liver fibrosis[J]. Journal of Clinical Hepatol. 2025, 41(1): 164-169 https://doi.org/10.12449/JCH250125

参考文献

列表( 原文顺序 | 文献年度倒序 | 文中引用次数倒序 ) 可视化分析
1
CHEN ZW, SUN H. Nrf2: A new target for nonalcoholic fatty liver disease[J]. Acta Pharm Sin, 2022, 57(11): 3268-3275. DOI: 10.16438/j.0513-4870.2022-0561 .
陈智伟, 孙华. Nrf2: 非酒精性脂肪性肝病的新靶点[J]. 药学学报, 2022, 57(11): 3268-3275. DOI: 10.16438/j.0513-4870.2022-0561 .
本文引用 [2]
2
ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. DOI: 10.1053/j.gastro.2019.11.312 .
本文引用 [1]
3
REN Q, WANG HY, ZENG Y, et al. Circulating chemerin levels in metabolic-associated fatty liver disease: A systematic review and meta-analysis[J]. Lipids Health Dis, 2022, 21(1): 27. DOI: 10.1186/s12944-022-01637-7 .
本文引用 [1]
4
ZHU XJ, QIU H, LIU SL, et al. Research progress of Chemerin in polycystic ovary syndrome[J]. Acta Physiol Sin, 2024, 76(3): 429-437. DOI: 10.13294/j.aps.2024.0001 .
朱晓娟, 邱杭, 刘圣兰, 等. Chemerin在多囊卵巢综合征中的研究进展[J]. 生理学报, 2024, 76(3): 429-437. DOI: 10.13294/j.aps.2024.0001 .
本文引用 [1]
5
QIU H, ZHU XJ, TONG TT, et al. Research progress of Chemerin protein and related diseases[J]. J Med Res Combat Trauma Care, 2023, 36(6): 638-643. DOI: 10.16571/j.cnki.2097-2768.2023.06.016 .
邱杭, 朱晓娟, 佟天天, 等. Chemerin蛋白与相关疾病研究进展[J]. 医学研究与战创伤救治, 2023, 36(6): 638-643. DOI: 10.16571/j.cnki.2097-2768.2023.06.016 .
本文引用 [1]
6
WANG W, ZHANG J, PU C. Expression of Visfatin and Chemerin in serum, umbilical blood and placenta of patients with gestational diabetes mellitus and the mechanism of insulin resistance[J]. J Mod Lab Med, 2022, 37(1): 21-27. DOI: 10.3969/j.issn.1671-7414.2022.01.005 .
王伟, 张静, 浦春. 妊娠糖尿病患者血清、脐血及胎盘组织中Visfatin和Chemerin的表达与胰岛素抵抗发生机制的研究[J]. 现代检验医学杂志, 2022, 37(1): 21-27. DOI: 10.3969/j.issn.1671-7414.2022.01.005 .
本文引用 [2]
7
BAI XL, CHEN F, ZHANG LR, et al. Research progress of Chemerin in nervous system diseases[J]. J Neurosci Ment Health, 2024, 24(2): 127-132.
柏晓林, 陈凤, 张力壬, 等. Chemerin在神经系统疾病中的研究进展[J]. 神经疾病与精神卫生, 2024, 24(2): 127-132.
本文引用 [1]
8
ZHAO MY, LI YM, LIU HY, et al. Research progress of insulin resistance markers in atherogenesis[J]. Basic Clin Med, 2022, 42(8): 1302-1305. DOI: 10.16352/j.issn.1001-6325.2022.08.1302 .
赵茂宇, 李佑美, 刘焕云, 等. 胰岛素抵抗标志物在动脉粥样硬化发病中的研究进展[J]. 基础医学与临床, 2022, 42(8): 1302-1305. DOI: 10.16352/j.issn.1001-6325.2022.08.1302 .
本文引用 [3]
9
HELFER G, WU QF. Chemerin: A multifaceted adipokine involved in metabolic disorders[J]. J Endocrinol, 2018, 238(2): R79-R94. DOI: 10.1530/JOE-18-0174 .
本文引用 [1]
10
XU ZJ, CHEN XB, CAI BJ, et al. Research progress in the relationship between all-trans retinoic acid and liver diseases and the associated molecular mechanisms[J]. Chin J Gen Surg, 2021, 30(7): 858-865. DOI: 10.7659/j.issn.1005-6947.2021.07.012 .
许召君, 陈小彬, 才保加, 等. 全反式维甲酸与肝脏疾病的关系及其分子机制研究进展[J]. 中国普通外科杂志, 2021, 30(7): 858-865. DOI: 10.7659/j.issn.1005-6947.2021.07.012 .
本文引用 [1]
11
ZHAO XA. Curcumin inhibits hepatic fibrosis by inhibiting monocyte infiltration and reducing monocyte-derived GRN secretion[D]. Nanjing: Nanjing University of Chinese Medicine, 2019.
赵祥安. 姜黄素抑制单核细胞浸润并减少单核细胞来源GRN分泌抗肝纤维化的机制研究[D]. 南京: 南京中医药大学, 2019.
本文引用 [2]
12
NIU YY, FAN ZK, WANG LD, et al. Research progress on induced hepatic stellate cell ferroptosis in prevention and treatment of liver fibrosis[J]. China J Chin Mater Med, 2024, 49(9): 2281-2289. DOI: 10.19540/j.cnki.cjcmm.20240208.601 .
牛媛媛, 樊泽坤, 汪龙德, 等. 诱导肝星状细胞铁死亡在肝纤维化防治中的研究进展[J]. 中国中药杂志, 2024, 49(9): 2281-2289. DOI: 10.19540/j.cnki.cjcmm.20240208.601 .
本文引用 [1]
13
QIN LJ, ZHANG L, HOU P, et al. Research progress in pathogenesis of liver fibrosis[J]. J Jilin Med Univ, 2021, 42(5): 369-371. DOI: 10.13845/j.cnki.issn1673-2995.2021.05.019 .
秦利静, 张露, 侯鹏, 等. 肝纤维化发病机制的研究进展[J]. 吉林医药学院学报, 2021, 42(5): 369-371. DOI: 10.13845/j.cnki.issn1673-2995.2021.05.019 .
本文引用 [1]
14
HAO SD, LIU CP, LI YT, et al. Research progress of hepatic stellate cell activation-related signal pathways in liver fibrosis[J]. Chin J Gastroenterol Hepatol, 2022, 31(2): 131-135. DOI: 10.3969/j.issn.1006-5709.2022.02.003 .
郝少东, 刘彩萍, 李月廷, 等. 肝星状细胞活化相关信号通路在肝纤维化中的研究进展[J]. 胃肠病学和肝病学杂志, 2022, 31(2): 131-135. DOI: 10.3969/j.issn.1006-5709.2022.02.003 .
本文引用 [1]
15
YI YF, CHEN CL. Study of serum chemerin and hs-CRP in patients with nonalcoholic fatty liver disease complicating insulin resistance[J]. Chongqing Med, 2017, 46(2): 172-174. DOI: 10.3969/j.issn.1671-8348.2017.02.008 .
易玉芳, 陈春莲. 非酒精性脂肪肝病合并胰岛素抵抗患者血清chemerin和hs-CRP水平的研究[J]. 重庆医学, 2017, 46(2): 172-174. DOI: 10.3969/j.issn.1671-8348.2017.02.008 .
本文引用 [3]
16
WANG YJ, LI LX. Mechanisms of adipokines regulating inflammation in non-alcoholic fatty liver disease[J]. Med Recapitul, 2022, 28(13): 2516-2522. DOI: 10.3969/j.issn.1006-2084.2022.13.004 .
王羽洁, 李连喜. 调控炎症的脂肪因子在非酒精性脂肪性肝病中的作用机制[J]. 医学综述, 2022, 28(13): 2516-2522. DOI: 10.3969/j.issn.1006-2084.2022.13.004 .
本文引用 [2]
17
LI ZY, LIANG XM, LI X, et al. Expression of serine protease inhibitors, endothelins and chemerin in T2DM patients with NAFLD and analysis of their relationship with insulin resistance[J]. Anhui Med Pharm J, 2021, 25(11): 2265-2269. DOI: 10.3969/j.issn.1009-6469.2021.11.033 .
李曾一, 梁新明, 李星, 等. 血清丝氨酸蛋白酶抑制剂、内脂素、趋化素在2型糖尿病并发非酒精性脂肪性肝病中的表达及与胰岛素抵抗的关系[J]. 安徽医药, 2021, 25(11): 2265-2269. DOI: 10.3969/j.issn.1009-6469.2021.11.033 .
本文引用 [1]
18
QIANG HM, TANG JW, ZHAO R, et al. Effect of the adjuvant Baogan Jiangzhi decoction therapy on liver function and insulin sensitivity in patients with nonalcoholic fatty liver disease[J]. J Hainan Med Univ, 2018, 24(6): 707-710. DOI: 10.13210/j.cnki.jhmu.20180327.009 .
强红梅, 唐军伟, 赵荣, 等. 保肝降脂汤辅助治疗对非酒精性脂肪肝病患者肝功能、胰岛素敏感性的影响[J]. 海南医学院学报, 2018, 24(6): 707-710. DOI: 10.13210/j.cnki.jhmu.20180327.009 .
本文引用 [1]
19
LI XH, CHEN Z, ZHAO L, et al. The relationship between the expression of Chemerin, IRS-1, IRS-2 and p-Akt and insulin resistance in the placenta in pregnant women with GDM[J]. Chin J Diabetes, 2020, 28(6): 405-409. DOI: 10.3969/j.issn.1006-6187.2020.06.002 .
李晓红, 陈卓, 赵琳, 等. 妊娠期糖尿病患者胎盘组织中趋化素、胰岛素受体底物1、胰岛素受体底物2和磷酸化蛋白激酶B的表达及与胰岛素抵抗的关系[J]. 中国糖尿病杂志, 2020, 28(6): 405-409. DOI: 10.3969/j.issn.1006-6187.2020.06.002 .
本文引用 [1]
20
XING DJ, SUN YH, YU LG, et al. Changes of serum Chemerin level in patients with nonalcoholic fatty liver disease and its relationship with insulin resistance and inflammation[J]. Mod Med J China, 2021, 23(8): 23-26. DOI: 10.3969/j.issn.1672-9463.2021.08.006 .
邢冬杰, 孙英红, 于龙广, 等. 非酒精性脂肪性肝病患者血清趋化素水平变化及其与胰岛素抵抗、炎症的关系研究[J]. 中国现代医药杂志, 2021, 23(8): 23-26. DOI: 10.3969/j.issn.1672-9463.2021.08.006 .
本文引用 [2]
21
WEI Y, ZHANG JC, LI XJ, et al. Research progress of traditional Chinese medicine on alleviating insulin resistance based on classical insulin conduction and inflammatory signal pathway[J]. Mod Tradit Chin Med Mater Med World Sci Technol, 2022, 24(5): 2026-2034.
魏颖, 张嘉诚, 李晓娟, 等. 基于经典胰岛素传导及炎症信号通路的相互作用中药改善胰岛素抵抗作用研究进展[J]. 世界科学技术-中医药现代化, 2022, 24(5): 2026-2034.
本文引用 [3]
22
LI HX, WEI J, HA XQ. Current research status of chemokines and metabolic diseases[J]. Chin Med Biotechnol, 2020, 15(5): 508-511. DOI: 10.3969/j.issn.1673-713X.2020.05.012 .
李海霞, 魏静, 哈小琴. 趋化素与代谢性疾病的研究现状[J]. 中国医药生物技术, 2020, 15(5): 508-511. DOI: 10.3969/j.issn.1673-713X.2020.05.012 .
本文引用 [1]
23
WU Z, HU XB, CAO ZH. The role of oxidative stress in pancreatic β cells and type 1 diabetes mellitus[J]. Prog Microbiol Immunol, 2019, 47(6): 87-90. DOI: 10.13309/j.cnki.pmi.2019.06.016 .
吴颛, 胡小波, 曹朝晖. 胰岛β细胞氧化应激反应及其在1型糖尿病中的作用[J]. 微生物学免疫学进展, 2019, 47(6): 87-90. DOI: 10.13309/j.cnki.pmi.2019.06.016 .
本文引用 [1]
24
HUANG HC, ZHANG Z, ZHANG XZ, et al. Sinapine thiocyanate inhibits hyperlipidemia, hyperglycemia, atherosclerosis and hepatocellular steatosis in IR mice[J]. Chin J Pathophysiol, 2018, 34(1): 1-8. DOI: 10.3969/j.issn.1000-4718.2018.01.001 .
黄涵柽, 张祝, 张希洲, 等. 芥子碱硫氰酸盐抑制IR小鼠血脂血糖升高、动脉粥样硬化及肝细胞脂肪变性[J]. 中国病理生理杂志, 2018, 34(1): 1-8. DOI: 10.3969/j.issn.1000-4718.2018.01.001 .
本文引用 [1]
25
LI XX, ZHU QL, WANG WS, et al. Elevated chemerin induces insulin resistance in human granulosa-lutein cells from polycystic ovary syndrome patients[J]. FASEB J, 2019, 33(10): 11303-11313. DOI: 10.1096/fj.201802829R .
本文引用 [1]
26
CIGNARELLI A, GENCHI VA, PERRINI S, et al. Insulin and insulin receptors in adipose tissue development[J]. Int J Mol Sci, 2019, 20(3): 759. DOI: 10.3390/ijms20030759 .
本文引用 [2]
27
JIA J, YU F, XIONG Y, et al. Chemerin enhances the adhesion and migration of human endothelial progenitor cells and increases lipid accumulation in mice with atherosclerosis[J]. Lipids Health Dis, 2020, 19(1): 207. DOI: 10.1186/s12944-020-01378-5 .
本文引用 [1]
28
WU HY, YANG YF. Research progress on the relationship between free fatty acids and insulin resistance[J]. J Liaoning Univ Tradit Chin Med, 2023, 25(3): 147-151. DOI: 10.13194/j.issn.1673-842x.2023.03.029 .
吴海燕, 杨宇峰. 游离脂肪酸和胰岛素抵抗相关性研究进展[J]. 辽宁中医药大学学报, 2023, 25(3): 147-151. DOI: 10.13194/j.issn.1673-842x.2023.03.029 .
本文引用 [1]
29
ZHU L, HUANG JF, WANG Y, et al. Chemerin causes lipid metabolic imbalance and induces passive lipid accumulation in human hepatoma cell line via the receptor GPR1[J]. Life Sci, 2021, 278: 119530. DOI: 10.1016/j.lfs.2021.119530 .
本文引用 [2]
30
LI HL, DONG LL, YANG XH, et al. Relationship of peripheral blood Chemerin with glucose and lipid metabolism, visceral fat, oxidative stress and inflammatory indexes in diabetic patients with MAFLD disease[J]. J Hebei Med Univ, 2022, 43(3): 275-279, 294. DOI: 10.3969/j.issn.1007-3205.2022.03.006 .
李海玲, 董陆玲, 杨秀红, 等. 糖尿病合并MAFLD患者外周血Chemerin与糖脂代谢、内脏脂肪、氧化应激及炎症指标的关系[J]. 河北医科大学学报, 2022, 43(3): 275-279, 294. DOI: 10.3969/j.issn.1007-3205.2022.03.006 .
本文引用 [1]
31
SERAFIN DS, ALLYN B, SASSANO MF, et al. Chemerin-activated functions of CMKLR1 are regulated by G protein-coupled receptor kinase 6 (GRK6) and β-arrestin 2 in inflammatory macrophages[J]. Mol Immunol, 2019, 106: 12-21. DOI: 10.1016/j.molimm.2018.12.016 .
本文引用 [1]
32
KARAMFILOVA V, NEDEVA I, ASSYOV Y, et al. Chemerin in obese patients with nonalcoholic fatty liver disease with or without prediabetes[J]. CR Acad Bulg Sci, 2024, 77(1): 127-136.
本文引用 [1]
33
YANG YM, WANG X, MA J. Research progress on the role of M1/M2 macrophages in hepatic fibrosis[J]. Med J Chin PLA, 2024, 49(6): 726-732. DOI: 10.11855.j.issn.0577-7402.1239.2024.0124 .
杨钰萌, 王新, 麻婧. M1/M2型巨噬细胞在肝纤维化中的作用研究进展[J]. 解放军医学杂志, 2024, 49(6): 726-732. DOI: 10.11855.j.issn.0577-7402.1239.2024.0124 .
本文引用 [1]
34
WU MB, ZHANG WF, GONG JP, et al. Wortmannin inhibits the activity of NLRP3 in Kupffer cells through the Chemerin/CMKLR1 pathway and relieves nonalcoholic fatty liver in mice[J]. Chongqing Med, 2018, 47(17): 2279-2284. DOI: 10.3969/j.issn.1671-8348.2018.17.007 .
吴明兵, 张文锋, 龚建平, 等. 渥曼青霉素通过Chemerin/CMKLR1途径抑制Kupffer细胞NLRP3的活性缓解小鼠非酒精性脂肪肝[J]. 重庆医学, 2018, 47(17): 2279-2284. DOI: 10.3969/j.issn.1671-8348.2018.17.007 .
本文引用 [1]
35
XU J, JIN WL, LI X. A new perspective in the treatment of liver fibrosis: Targeting macrophage metabolism[J]. J Clin Hepatol, 2023, 39(4): 922-928. DOI: 10.3969/j.issn.1001-5256.2023.04.027 .
许钧, 金卫林, 李汛. 肝纤维化治疗的新视角: 靶向巨噬细胞代谢[J]. 临床肝胆病杂志, 2023, 39(4): 922-928. DOI: 10.3969/j.issn.1001-5256.2023.04.027 .
本文引用 [1]
36
XIANG YL, DAI X, GONG JP. The role of Kupffer cells in the pathogenesis of MAFLD[J]. Clin Res Pract, 2021, 6(20): 195-198. DOI: 10.19347/j.cnki.2096-1413.202120061 .
向阳林, 代鑫, 龚建平. Kupffer细胞在MAFLD发病机制中的作用[J]. 临床医学研究与实践, 2021, 6(20): 195-198. DOI: 10.19347/j.cnki.2096-1413.202120061 .
本文引用 [1]
37
POHL R, FEDER S, HABERL EM, et al. Chemerin overexpression in the liver protects against inflammation in experimental non-alcoholic steatohepatitis[J]. Biomedicines, 2022, 10(1): 132. DOI: 10.3390/biomedicines10010132 .
本文引用 [1]
38
HABERL EM, POHL R, REIN-FISCHBOECK L, et al. Overexpression of hepatocyte chemerin-156 lowers tumor burden in a murine model of diethylnitrosamine-induced hepatocellular carcinoma[J]. Int J Mol Sci, 2019, 21(1): 252. DOI: 10.3390/ijms21010252 .
本文引用 [1]
39
WU MQ, YANG QR, XU SM, et al. Role of serum Chemerin and related inflammatory factors in non-alcoholic fatty liver disease[J]. J Med Res, 2021, 50(12): 60-63. DOI: 10.11969/j.issn.1673-548X.2021.12.014 .
吴明奇, 杨晴柔, 徐素美, 等. 血清趋化素Chemerin及相关炎性细胞因子在非酒精性脂肪性肝病中的作用[J]. 医学研究杂志, 2021, 50(12): 60-63. DOI: 10.11969/j.issn.1673-548X.2021.12.014 .
本文引用 [1]
40
DOU B, MA CY, HOU WX, et al. Effects of Jieduan niwan prescription drug containing serum on oxidative stress injury of L02 cells based on TLR4/NF-‍κB/iNOS pathway[J]. Chin J Inf Tradit Chin Med, 2022, 29(4): 87-91. DOI: 10.19879/j.cnki.1005-5304.202110034 .
窦博, 马重阳, 侯伟欣, 等. 基于TLR4/NF-κB/iNOS通路的截断逆挽方药物血清对L02细胞氧化应激损伤的影响[J]. 中国中医药信息杂志, 2022, 29(4): 87-91. DOI: 10.19879/j.cnki.1005-5304.202110034 .
本文引用 [1]
41
SPIRK M, ZIMNY S, NEUMANN M, et al. Chemerin-156 is the active isoform in human hepatic stellate cells[J]. Int J Mol Sci, 2020, 21(20): E7555. DOI: 10.3390/ijms21207555 .
本文引用 [1]
42
KUKLA M, MAZUR W, BUŁDAK RJ, et al. Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis[J]. Mol Med, 2011, 17(11-12): 1397-410. DOI: 10.2119/molmed.2010.00105 .
本文引用 [1]
43
NAGARAJAN SR, PAUL-HENG M, KRYCER JR, et al. Lipid and glucose metabolism in hepatocyte cell lines and primary mouse hepatocytes: A comprehensive resource for in vitro studies of hepatic metabolism[J]. Am J Physiol Endocrinol Metab, 2019, 316(4): E578-E589. DOI: 10.1152/ajpendo.00365.2018 .
本文引用 [1]

作者贡献声明

张欣媛负责设计论文框架，撰写论文；张诺琪、于国慧、任文帅负责文献检索，格式校对，提供修改意见；王亚玲负责指导撰写文章并校审。

评论

PDF(904 KB)

Accesses

Citation

Detail
段落导航
相关文章
Copyright 中国高校科技期刊信息汇聚平台 2024-2025
技术支持：北京玛格泰克科技发展有限公司
京ICP备05021913号-19

/

〈 〉